Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PDUFA VI: Industry Ready For 'Hard Sell' To Keep Agreement Intact

Executive Summary

Biopharma industry is preparing for the unwelcome possibility that the new Congress and Trump Administration will seek to revisit provisions in the negotiated agreement for the US FDA user fee program's reauthorization.


Related Content

Current FDA Policy Uncertainties Could Yield 'Reverse Impact' Of Support
Obamacare Repeal May Be Delaying User Fee Bill, Rep. DeGette Says
Drug Pricing Bill May Make Six-Month ANDA Review Slower Than Eight-Month Review
Woodcock, Califf Give Thumbs Up To Certain 21st Century Cures Provisions
Trump’s Rx For The Drug Industry: Take Two And Have No Idea What Will Happen In The Morning
Possible Trump FDA Commish Candidate Favors (Much) Lighter Touch
PDUFA Acronym War Begins: Could Reauthorization Be Called Patient-UFA?
ANDAs Can Get Priority, Eight-Month Reviews Under User Fee Deal
You Just Have To Wait: FDA Can't Hurry PDUFA VI Guidances
FDA To Join The 'Real World' Under PDUFA VI


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts